Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis - Université de Lorraine Accéder directement au contenu
Article Dans Une Revue The Lancet Gastroenterology & Hepatology Année : 2022

Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis

Résumé

There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with moderate-to-severe ulcerative colitis.
None.
Fichier non déposé

Dates et versions

hal-04165536 , version 1 (19-07-2023)

Identifiants

Citer

Juan Lasa, Pablo Olivera, Silvio Danese, Laurent Peyrin-Biroulet. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. The Lancet Gastroenterology & Hepatology, 2022, 7 (2), pp.161-170. ⟨10.1016/S2468-1253(21)00377-0⟩. ⟨hal-04165536⟩
26 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More